What is Signify Bio?
Founded in 2025 and headquartered in Dallas, Texas, Signify Bio is at the forefront of biotechnology innovation, specializing in the development of in situ protein therapeutics. The company harnesses the body's inherent capacity to produce therapeutic proteins, employing proprietary platforms such as SEND (Signal peptide Engineered Nucleic acid Design) and iPhos lipid nanoparticles for precise, localized delivery. This approach facilitates targeted therapeutic interventions, aiming to address a spectrum of chronic and genetic disorders through sophisticated nucleic acid and protein engineering. Signify Bio's collaborative efforts with the University of Texas Southwestern Medical Center are geared towards pioneering personalized medicines.
How much funding has Signify Bio raised?
Signify Bio has raised a total of $15M across 1 funding round:
Other Financing Round
$15M
Other Financing Round (2025): $15M with participation from Danaher, Actium Group, BrightEdge, and Eli Lilly
Key Investors in Signify Bio
Danaher
Danaher Corporation is a global entity operating across biotechnology, life sciences, and diagnostics, providing integrated solutions for therapeutic product development and manufacturing. They offer bioprocess technologies, manufacturing support, and advanced analytical instrumentation.
Actium Group
Actium Group Corporation is a training and management consulting firm specializing in helping small and medium-sized businesses with practical solutions for growth and process optimization.
BrightEdge
ACS BrightEdge, the innovation and impact investment arm of the American Cancer Society, focuses on investing in scalable solutions to address unmet needs in cancer care and advance scientific discovery.
What's next for Signify Bio?
With this major enterprise-level funding, Signify Bio is poised to accelerate its research and development initiatives, further refine its proprietary platforms, and expand its clinical pipeline. The strategic investment signals strong confidence in the company's innovative therapeutic approach and its potential to disrupt the treatment landscape for complex diseases. Future endeavors will likely focus on advancing its personalized medicine offerings and solidifying its market position within the competitive biotechnology sector.
See full Signify Bio company page
